Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04118985
Other study ID # 19-006676
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 10, 2019
Est. completion date October 30, 2020

Study information

Verified date November 2020
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Researchers are trying to better understand if behavioral interventions can help improve memory compensation and engagement in healthy lifestyle behaviors in those with memory concerns but normal mental status exam.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date October 30, 2020
Est. primary completion date October 30, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - Age 50 or older - A positive complaint or concern in response to two questions ('Do you feel like your memory or other aspects of thinking are becoming worse?' and 'Does this worry you?') - Normal cognitive performance on the Montreal Cognitive Assessment (adjusted for age and education) - Self-reported independent function in daily life as measure by the Lawson IADL scale (IADL=8) - English speaking - Approval letter from a physician (due to the exercise component) Exclusion Criteria: - Known neurological disorder with potential cognitive symptoms (a diagnosis of Parkinson's disease, epilepsy, a history of significant TBI, etc.) - Uncontrolled moderate or severe depression (e.g., CES-D > 21).

Study Design


Intervention

Behavioral:
Cognitive rehabilitation and health behavior change intervention
Cognitive rehabilitation and health behavior change intervention in a group-based program intervention compared to self-implementation of techniques without these interventions
Self-implementation
Self-implementation of cognitive rehabilitation and health behavior change recommendations

Locations

Country Name City State
United States Mayo Clinic Scottsdale Arizona

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Everyday Compensation Questionnaire self-report and informant report if an informant is available of compensatory strategy use; range 0-148 with higher scores indicating more compensatory use baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months
Primary Lifestyle Activities Questionnaire self-report of cognitive activities, range 13-65 with higher scores indicating more activity baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months
Primary BrainHQ Number of minutes on BrainHQ computer exercise program baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months
Primary Physical Activities Questionnaire self-report of physical activity; scores include number of days per week across 7 activity types and number of minutes in each activity when completed. baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months
Primary Mindful Attention Awareness Scale self-report of mindfulness, range of 11-66 with higher scores indicating more mindful daily experience baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months
Secondary Everyday Cognition self-report of everyday functioning, range 39-156 with higher scores indicating more problems in daily functioning baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months
Secondary Quality of Life (in aging and cognitive health) self-report of quality of life, range of 13-52 with higher scores indicating better quality of life baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months
Secondary Psychological well-being self-report of psychological well-being/happiness; there is a total score plus subscales of autonomy, environmental mastery, personal growth, positive relations with others, purpose in life, self-acceptance. Each subscale has 9 items for a total of 54 items. Total scores range from 54-324 with higher scores indicating higher psychological well being. Each subscale ranges from 9-54 with higher scores indicating greater well-being on that construct. baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months
Secondary Centers for Epidemiological Studies - Depression self-report of symptoms of depression.Range 0-60 with higher scores indicating more depression baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months
Secondary Cognitive measure of memory Hopkins Verbal Memory test. Staff administered standardized verbal memory task. Scores include total words recalled and total recalled after a delay with higher scores indicating greater recall baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months
Secondary cognitive measure of executive functioning Trailmaking test; Staff administered standardized measure of attention and executive functioning. Scores include time to complete the task (with higher scores being slower) and number of errors baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months
Secondary cognitive measure of verbal fluency Controlled Oral Word Association Test; Staff administered standardized measure of speed and verbal fluency. Score is number of items in one minute with higher scores indicating better functioning baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months
Secondary cognitive measure of visual scanning speed Symbol Digit Modalities Test; Staff administered standardize measure of speed and visual scanning. Scores indicate number of items completed in the time frame with higher scores indicating better functioning. baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months
Secondary cognitive measure of response inhibition Stroop Color Word Test; Staff administered standardized measure of speed and response inhibition. Scores indicate number of items completed in the time limit with higher scores indicating better functioning baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months
See also
  Status Clinical Trial Phase
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A

External Links